Sector
PharmaceuticalsOpen
₹347.95Prev. Close
₹352.25Turnover(Lac.)
₹28,481.63Day's High
₹357.9Day's Low
₹34552 Week's High
₹404.752 Week's Low
₹291Book Value
₹95.96Face Value
₹5Mkt Cap (₹ Cr.)
42,669.32P/E
0EPS
0.41Divi. Yield
0.3516 May 2024
12:00 AM
AGM
Announcement Date: 16 May, 2024
2 Apr 2025
12:00 AM
Board Meeting
Agenda : Audited Result
In its filing with the bourses, the company reported that the current contract period of 36 months has been extended for an additional six months.
As per the company’s filing with the bourses, Biocon Biologics has developed and manufactured this injection while Yoshindo Inc.
The operating performance was also good as EBITDA increased 17.7% to ₹1,078.2 crore in March quarter compared with ₹915.9 crore in Q4 FY24.
Yesintek has been added to Express Scripts' National Preferred Formulary (NPF), effective March 21, 2025.
The fundraising may be executed in one or more tranches using QIP, rights issues, or any other permissible route under regulatory guidelines.
| Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
|---|---|---|---|---|
Equity Capital | 600.3 | 600.3 | 600.3 | 600 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 10,312 | 10,315.7 | 7,492.6 | 7,307.1 |
Net Worth | 10,912.3 | 10,916 | 8,092.9 | 7,907.1 |
Minority Interest |
| Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Revenue | 1,738.2 | 2,028.4 | 1,988.4 | 2,419.2 |
yoy growth (%) | -14.3 | 2.01 | -17.8 | -6.51 |
Raw materials | -808.2 | -798.3 | -827.7 | -1,049.4 |
As % of sales | 46.49 | 39.35 | 41.62 | 43.37 |
Employee costs | -367.7 | -390.2 | -344.8 | -408.6 |
| Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Profit before tax | 139.7 | 358.8 | 388.5 | 305.8 |
Depreciation | -108.2 | -103.5 | -98 | -136.1 |
Tax paid | -53.6 | -78.3 | -111.9 | -67.3 |
Working capital | 268.3 | 64.09 | 379.5 | -311.6 |
Other operating items |
| Y/e 31 Mar | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | -14.3 | 2.01 | -17.8 | -6.51 |
Op profit growth | -80.44 | 9.26 | -10.11 | -46.23 |
EBIT growth | -60.99 | -7.82 | 27.02 | -43.18 |
Net profit growth | -69.3 | -36.38 | 84.86 | -54.07 |
| Particulars (Rupees in Crores.) | Mar-2025 | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
|---|---|---|---|---|---|
Gross Sales | 15,052.2 | 14,195.8 | 11,174.2 | 8,184 | 7,143.1 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 15,052.2 | 14,195.8 | 11,174.2 | 8,184 | 7,143.1 |
Other Operating Income | 209.5 | 559.9 | 0 | 0 | 0 |
Other Income | 1,304.7 | 865.5 | 375.9 | 212.7 | 267.1 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,687.4 | 94.51 | 4,04,767.81 | 2,000.46 | 0.95 | 7,107.14 | 101.44 |
Divis Laboratories Ltd DIVISLAB | 6,725 | 80.79 | 1,78,467.89 | 667 | 0.45 | 2,536 | 561.08 |
Cipla Ltd CIPLA | 1,502.8 | 24.63 | 1,21,323.17 | 1,485.4 | 1.07 | 4,254.47 | 397.42 |
Dr Reddys Laboratories Ltd DRREDDY | 1,362.7 | 21.27 | 1,13,756.67 | 1,200.7 | 0.59 | 5,546.3 | 345.79 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,258.8 | 57.91 | 1,10,340.1 | 474 | 0.98 | 2,385 | 224.33 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Chairperson
Kiran Mazumdar Shaw
Non Executive Director
Ravi Mazumdar
Lead Independent Director
M Damodaran
Independent Director
Bobby Parikh
Company Sec. & Compli. Officer
Mayank Verma
Managing Director & CEO
SIDDHARTH MITTAL
Non Executive Director
Eric Vivek Mazumdar
Independent Director
Naina Lal Kidwai
Independent Director
Atul Dhawan
Independent Director
Rekha Mehrotra Menon
Independent Director
NICHOLAS ROBERT HAGGAR
20th KM Hosur Road Hebbagodi,
Electronic City P O,
Karnataka - 560100
Tel: 91-80-28082808
Website: http://www.biocon.com
Email: co.secretary@biocon.com
Karvy Selenium Tow-B,
31&32 Financial Dist, Nanakramguda,
Hyderabad-500032
Tel: 91-40-67162222
Website: www.kfintech.com
Email: einward.ris@kfintech.com
Summary
Biocon Limited is Indias largest and fully-integrated, innovation-led biopharmaceutical company. Biocon, with its key business verticals ofGenerics, Biosimilars, Research Services and Novel Biologics,...
Read More
Reports by Biocon Ltd
What is the Biocon Ltd share price today?
What is the Market Cap of Biocon Ltd?
What is the PE and PB ratio of Biocon Ltd?
What is the 52 Week High and Low of Biocon Ltd?
What is the CAGR of Biocon Ltd?
What is the shareholding pattern of Biocon Ltd?
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
